Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Wilex was founded in September 1997 by Dr Olaf G Wilhelm, Prof Dr Manfred Schmitt and Dr Viktor Magdolen as a spin-off from the Clinical Research Unit of the Department for Gynaecology of the Technical University of Munich (TUM). Wilex is a biopharmaceutical company dedicated to the development and commercialisation of novel cancer therapies to treat specific patient subpopulations identified by molecular characterisation of their primary tumour.